In October 2025, the World Health Organization reported that one in six laboratory-confirmed bacterial infections worldwide was already resistant to the antibiotics meant to treat it [source: World Health Organization, 2025]. That single statistic captures a quiet emergency. Antimicrobial resistance (AMR) does not arrive as a sudden outbreak with a name and a map. It advances slowly, infection by infection, as the drugs that have underpinned modern medicine for eighty years gradually stop working. A year earlier, in September 2024, world leaders gathered at the United Nations and did something they had never done before: they agreed to a hard number, pledging to cut deaths linked to bacterial resistance by 10% by 2030 [source: United Nations Environment Programme, 2024]. The gap between that promise and the surveillance data is what makes this the moment to pay attention.
This article separates what we actually measure from what we model, treats the fierce debate over farm antibiotics with care, and lays out the competing ideas for fixing a drug pipeline that has nearly run dry.
In this article
- What resistance is, and why it is not the flu
- The numbers: measured versus modeled
- Why now: a decade of warnings meets a policy moment
- The One Health tangle: hospitals, farms, and the environment
- The broken pipeline: why new antibiotics are not coming
- What would actually move the needle
- Conclusion: what to watch
What resistance is, and why it is not the flu
Antibiotics work by killing bacteria or stopping them from multiplying. But bacteria reproduce in minutes and swap genetic material readily, so any survivor of a drug can pass on the traits that saved it. Use an antibiotic and you inevitably select for the bugs it cannot kill. This is evolution on fast-forward, and it is why resistance is often called a "slow pandemic": there is no single virus to sequence, only a rising tide of ordinary infections — urinary tract infections, pneumonia, bloodstream infections, gonorrhoea — that become harder, more expensive, and sometimes impossible to cure.
The consequence is not just about exotic diseases. Routine surgery, chemotherapy, childbirth, and organ transplants all rely on antibiotics working in the background to prevent and treat infection. When they fail, the risk of everyday medicine climbs. That is why the WHO frames AMR not as one disease but as a threat to the entire foundation of modern care [source: World Health Organization, 2025].
The numbers: measured versus modeled
Any honest account of AMR has to keep two kinds of figures apart — what surveillance systems actually count, and what statistical models project into the future. They tell related but different stories, and conflating them is the most common mistake in AMR coverage.
What we measure
The measured picture is already sobering. WHO's Global Antibiotic Resistance Surveillance System (GLASS) found that across eight common bacterial pathogens and 22 antibiotics, one in six confirmed infections in 2023 was resistant, and that resistance rose in more than 40% of the drug–bug combinations it tracks between 2018 and 2023, at an average of 5–15% per year [source: World Health Organization, 2025]. The burden is uneven: resistance affected roughly one in three infections in WHO's South-East Asia and Eastern Mediterranean regions, one in five in Africa, and one in seven in the Americas [source: World Health Organization, 2025].
A concrete example comes from the United States. The Centers for Disease Control and Prevention reported in 2025 that infections from NDM-producing carbapenem-resistant Enterobacterales — a group so hard to treat that clinicians nicknamed them "nightmare bacteria" — rose more than 460% between 2019 and 2023 [source: US Centers for Disease Control and Prevention, 2025]. The NDM enzyme disables nearly all available antibiotics, leaving few or no options. For baseline scale, the CDC's threats reporting attributes more than 2.8 million resistant infections and over 35,000 deaths a year in the US alone [source: US Centers for Disease Control and Prevention, 2019].
One caveat sits under all of this: the map has holes. Only 104 countries reported to GLASS in 2023, and nearly half of the world's countries did not submit usable data, with coverage weakest in Africa and parts of the Western Pacific [source: World Health Organization, 2025]. Where surveillance is thin, the true burden is likely underestimated, not absent.
What we model
The headline forecasts come from statistical modeling, and they deserve both attention and skepticism. The most rigorous is the Global Research on Antimicrobial Resistance (GRAM) study, published in The Lancet in September 2024. It estimated that bacterial resistance directly caused more than a million deaths every year between 1990 and 2021, and forecast 39 million cumulative deaths directly attributable to AMR between 2025 and 2050 — roughly three every minute [source: The Lancet, 2024]. Direct annual deaths are projected to reach 1.91 million by 2050, and deaths in which resistance plays a contributing role could climb to 8.22 million a year [source: The Lancet, 2024].
These are estimates with wide uncertainty bands, and the study is careful to distinguish deaths caused by resistance from the larger count associated with it. It also carries a crucial and more hopeful finding: under a scenario of better care for severe infections and better access to the right antibiotics, about 92 million of those projected deaths could be averted [source: The Lancet, 2024]. In other words, the model does not describe a fixed destiny.
It is worth remembering how a famous earlier number has been misused. The 2016 O'Neill Review, commissioned by the UK government, estimated AMR could cause up to 10 million deaths a year by 2050 [source: Review on Antimicrobial Resistance, 2016]. That figure has been repeated for a decade, often stripped of the context that it was a worst-case, no-action scenario rather than a base projection — and researchers have cautioned that AMR burden estimates carry large uncertainty [source: PLOS Medicine, 2016]. The lesson is not that the threat is overblown, but that the scary single number and the measured reality are different things and should be labeled as such.
One measured trend cuts against the gloom: between 1990 and 2021, AMR deaths in children under five fell by about half, thanks to vaccines, cleaner water, and better infection control [source: The Lancet, 2024]. Over the same period deaths in people over 70 rose by more than 80% — a reminder that the burden is shifting toward older, aging populations rather than growing uniformly.
Why now: a decade of warnings meets a policy moment
AMR has been on expert radar since Alexander Fleming himself warned about resistance in 1945. What makes 2024–2026 different is that the warnings collided with political action and worsening data at the same time. The September 2024 UN declaration was the second-ever high-level meeting on AMR and the first to set a concrete target — a 10% cut in resistance-associated deaths by 2030 — backed by a pledge of at least US$100 million in catalytic funding and a goal of having 60% of countries operate funded national action plans by 2030 [source: United Nations Environment Programme, 2024]. Then, through 2025, the WHO's surveillance and pipeline reports arrived to show how far there is to go.
Whether the declaration amounts to more than words is the open question. It is a political commitment, not binding law, and public-health analysts note that targets without sustained financing and enforcement have a poor track record. That tension — ambitious goals against thin follow-through — is the honest frame for "why now."
The One Health tangle: hospitals, farms, and the environment
Resistance does not respect the boundary between human and animal medicine. The dominant framework, endorsed by the UN's "Quadripartite" of the WHO, the World Organisation for Animal Health, the Food and Agriculture Organization, and the UN Environment Programme, is called One Health: the recognition that human, animal, and environmental resistance are linked [source: United Nations Environment Programme, 2024].
Livestock account for a large share of global antibiotic consumption — an estimated 99,502 tonnes in food-producing animals in 2020, projected to rise about 8% by 2030 under business as usual [source: PLOS Global Public Health, 2023]. The mechanism by which this breeds resistance is not in dispute: using antibiotics for growth promotion or routine disease prevention applies constant selective pressure, favoring resistant bacteria on farms.
Here, though, layering matters. The mechanism is established; the magnitude of the human toll from farm use specifically is genuinely contested. Resistance genes do move between animal, human, and environmental reservoirs, but scientists have found it hard to quantify how much human resistance is attributable to agriculture versus overuse in human medicine itself. Advocates for tighter farm rules point to the European Union's 2006 ban on antibiotic growth promoters as a model; critics counter that human clinical misuse — prescriptions for viral illnesses, incomplete courses, over-the-counter access in many countries — remains a major independent driver that farm reform alone will not fix. Both can be true. The responsible reading is that agriculture is one real pressure among several, not a single villain.
The broken pipeline: why new antibiotics are not coming
Even perfect stewardship would only buy time; the world also needs new drugs. Here the news is bleak. In its 2025 analysis, the WHO counted 90 antibacterial agents in clinical development, down from 97 in 2023 [source: World Health Organization, 2025]. Of those, only 15 were judged genuinely innovative, and just five were effective against at least one of the pathogens WHO classes as "critical" [source: World Health Organization, 2025]. For the most dangerous Gram-negative bacteria, the cupboard is nearly bare.
The reason is economic, not scientific. A new antibiotic is, commercially, a bad product: to slow resistance, doctors are told to use it as little as possible, so the drug that society needs most is the one it wants to sell least. Several large pharmaceutical companies have exited antibiotics entirely, and small biotechs that reach the market have gone bankrupt despite approvals. The pipeline is thin because the incentives are inverted.
Pull versus push
Two families of fixes are on the table, and the debate between them is unresolved. "Push" incentives fund research up front — grants and partnerships such as CARB-X and GARDP that de-risk early development. "Pull" incentives reward a successful drug at the finish line. The most-watched pull model is the United Kingdom's "Netflix-style" subscription, made a permanent NHS commissioning route in 2024, which pays a developer a fixed annual fee based on a drug's value to the health system rather than the volume sold — deliberately delinking revenue from prescriptions [source: NICE, 2024]. The United States has repeatedly proposed a similar scheme, the PASTEUR Act, but it has stalled in Congress for years [source: amr.solutions, 2024].
Most experts argue both push and pull are needed, and Europe is weighing "transferable exclusivity vouchers" as another pull mechanism [source: World Health Organization, 2025]. But none is a settled success. Critics question how much such schemes cost, whether they reward genuine innovation or minor tweaks, and — crucially — how new antibiotics would ever reach patients in the lower-income countries that carry the heaviest burden. Subsidizing invention in wealthy markets does not automatically solve global access.
What would actually move the needle
There is no single fix, but the evidence points to a portfolio. Better surveillance so that every country can see resistance in near real time, which WHO wants achieved by 2030 [source: World Health Organization, 2025]. Smarter use of existing drugs — WHO's AWaRe framework urges countries to make "Access" antibiotics at least 70% of consumption and rein in the broader-spectrum "Watch" drugs that drive resistance fastest [source: World Health Organization, 2025]. Basic infection prevention — clean water, sanitation, vaccination, and hospital hygiene — which is precisely what drove the halving of young-child deaths. Rapid diagnostics so clinicians prescribe the right drug instead of guessing. And a financing model that makes discovering new antibiotics viable without encouraging their overuse.
None of these is glamorous, and that is part of the problem: AMR competes for attention and money against threats with sharper edges. But the GRAM model's most important message is that a large share of the projected deaths is avoidable with tools that already exist [source: The Lancet, 2024].
Conclusion: what to watch
Antimicrobial resistance is the rare crisis where the science is clear, the trajectory is measurable, and the solutions are largely known — yet progress is slow because the incentives and attention are misaligned. Over the next few years, a handful of signals will show whether the 2024 promises translate into results: whether resistance-associated deaths bend toward the UN's 10% reduction target by 2030; whether GLASS surveillance finally covers the countries now in the dark; whether the drug pipeline produces anything effective against critical Gram-negative pathogens; and whether pull incentives spread beyond one or two countries into a system that also serves the poorest patients. Superbugs are winning slowly. The open question is whether the response can speed up.